Full Press Release Details
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Proprietary Radioligand Platform Optimizes Therapeutic Index
Proprietary Pb-Based Chelator Designed for Broader and Safer Use
Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters
Imaging Optimizes Targeted Delivery to Tumor
Solid Tumors are an Attractive Market for Radiopharmaceuticals
End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway
Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
VMT- -NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT- -NET in NETs
Compelling Anti-tumor Activity with Sustained or Deepening Responses
Best-in-class Safety Profile1
VMT- -NET's Compelling Profile Supports Potential Registration Study at Current Dose Level
Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01
Treatment Emergent Adverse Events (All Grades, Occurring in 2 Patients)
VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
FAP- is an Attractive Cancer Target with Broad Solid Tumor Potential
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP- for Solid Tumors
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026